Feasibility of extracorporeal hemocorrection in oncologic patients with paraneoplastic syndromes


E.G. Gromova

N.N. Blokhin Cancer Research Center, The Ministry of Healthcare of Russian Federation, Moscow, Russia

For citation: Gromova EG. Feasibility of extracorporeal hemocorrection in oncologic patients with paraneoplastic syndromes. Intensive Care Herald. 2016;1:17–20.

Paraneoplastic syndromes (PS) are associated with different oncologic diseases. PS have diverse clinical manifestations, are difficult to diagnose and often determine the tactics of treatment and prognosis. Etiology and pathogenesis of majority of PS are associated with the accumulation of pathological immune complexes. Prompt extracorporeal elimination of these complexes may improve the clinical course in many cases, facilitate adequate oncologic treatment and prevent the development of irreversible damage.

Keywords: oncology, paraneoplastic syndrome, extarcorporeal hemocorrection.


  1. Mitchell, R.S., Kumar, V., Abbas, A.K., et al. Robbins Basic Pathology.- Philadelphia: Saunders, 2007, 8th edition.
  2. Pranzatelli M.R. Paraneoplastic syndromes: An Unsolved Murder// Seminars in Pediatric Neurology. 2000. Vol.7, № 2, P. 118-130.
  3. Wong A. An update on opsoclonus. Curr Opin Neurol 2007; 20(1):25-31.
  4. Blaes F., Pike M.G., Lang B. Autoantibodies in childhood opsoclonus-myoclonus syndrome. J Neuroimmunol 2008; 201:221-6.
  5. Myrna R., Josep D. Update on Paraneoplastic Neurologic Disorders. The Oncologist 2010; 15: 603-617.
  6. Senties-Madrid H., Vega-Boada F. Paraneoplastic syndromes associated with anti-Hu antibodies. Isr Med Assoc J. 2001 Feb; 3(2):94-103.
  7. Pittock S.J., Lucchinetti C.F., Lennon V. Antineuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. 2003; 53(5): 580-587.
  8. Helmar C., Lehmann, MD; Hans-Peter Hartung, MD; et al. Plasma Exchange in Neuroimmunological Disorders/Neurological Review Arch Neurol. 2006; 63(7): 930-935.
  9. Miyamoto, Kato T., Watanabe H. et al. A case of paraneoplastic syndrome accompanied by two types of cancer//Neurol Neurosurg Psychiatry 2002; 72: 408-409.
  10. Miller F.W., Leitman S.F., Cronnin M.E., et al.: Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J. Med 326:1380-1384, 1982.
  11. Batchelor T.T., Platten M., Hochberg F.H.: Immunoadsorption therapy for paraneoplastic syndromes. J Neurooncol 40:131-136, 1998.
  12. Sheela S.R., Mani P.J.: Opsoclonus Mioclonus Syndrome: Response to Plasmapheresis. Indian Ped., vol.4, P.499-502, 2004.
  13. Yiu V.W.Y., Kovithavongs T., McGonigle L.F., et al.: Plasmapheresis as an effective treatment for idiopathic opsoclonus-myoclonus syndrome. Pediatr Neurol 2001; 24:72-74.
  14. Honorat J., Antoine, J.C. Paraneoplastic neurological syndromes //Orphanet J Rare Dis. 2007, № 4, P. 2-22.
  15. Vernino S. Paraneoplastic disorders affecting the neuromuscular junction or anterior horn cell //Continuum lifelong Learning Neurol. 2009 N 15(1), P127-141.